Funding for this research was provided by:
Wellcome Trust (103838)
NIHR Cambridge MRC CBU
Cambridge Center for Parkinson Plus
Patrick Berthoud Charitable Trust
Received: 1 July 2020
Accepted: 15 November 2020
First Online: 22 December 2020
Ethics approval and consent to participate
: The East of England institutional review boards approved the NIMROD (13/EE/0104), TENDER (16/EE/0529) and SENDER (18/EE/0059) protocols and written informed consent was obtained from all participants prior to inclusion.
: All subjects included in the present study have signed a consent form for publication.
: N. N., N.H., G.S., S.F.C., E.M., Y.T.H., S.M.S. and T.D.F. declare that they have no conflict of interests. F.I.A. received academic grant support from GE Healthcare and served as a consultant for Avid and Cantabio, all for matters not related to the current study. J.B.R. has been a consultant for Asceneuron and Syncona and has received academic grant funding from AZ-MedImmune, Janssen and Lilly, unrelated to this study. J.T.O. reports personal fees from TauRx, personal fees from Axon, personal fees from GE Healthcare, grants and personal fees from Avid/Lilly, personal fees from Eisai, grants from Alliance Medical, personal fees from Roche and grants from Merck, outside the submitted work.